Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum
tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and
anti-tumor activity of the combination.